• GEHA v. Actelion Pharmaceuticals (D. Md.). Representing Janssen Pharmaceuticals and subsidiaries in defense monopolization claims claiming delayed entry of generic of Actelion’s Tracleer product.
    • United States v. Google Inc. (D.D.C.). Representing Microsoft as a third-party in the Department of Justice’s antitrust action challenging Google’s alleged monopolization of the search market.
    • In re Opana ER Antitrust Litigation (N.D. Ill.). Represented a brand pharmaceutical company in its defense of class actions based on an alleged “reverse payment” patent litigation settlement. Secured complete defense verdict after four-week trial in federal court in Chicago.
    • In re Generic Pharmaceutical Pricing Antitrust Litigation. (E.D. Pa.). Defending a generic pharmaceutical company in multi-district litigation, brought by private plaintiffs and state attorneys generals, involving an alleged price fixing and supply reduction conspiracy.
    • In re Caustic Soda Antitrust Litigation (W.D.N.Y.). Defending a large chemical manufacturer in class action cases brought by direct and indirect purchasers claiming it participated in a price-fixing and supply reduction conspiracy in the caustic soda market.
    • FTC v. Endo Pharmaceuticals (D.D.C.). Representing a brand pharmaceutical company in novel action brought by Federal Trade Commission challenging a patent licensing agreement. Secured dismissal of all claims with prejudice; matter is currently on appeal.
    • Dana Farber Cancer Inst. V. Bristol-Meyers Squibb (D. Mass.). Represented Dana Farber in unfair competition claims related to inventorship of six immunology patents. The case resolved prior to trial.
    • Mish International Monetary v. Vega Capital London (N.D. Ill.). Representing 12 individual commodities futures traders against putative class claims under the Sherman Antitrust Act and the Commodities Exchange Act based on trading of West Texas Intermediate Crude Oil futures contracts.
    • FTC v. Meta (D.D.C.). Representing technology company as a non-party in the Federal Trade Commission’s antitrust action against Meta.
    • In re Amitiza Antitrust Litigation (D. Mass.). Represented a generic pharmaceutical company in defense of claims brought on behalf of direct purchasers challenging an alleged “reverse payment” patent litigation settlement.
    • In re Colcrys Antitrust Litigation (E.D. Pa.). Represented a generic pharmaceutical company in defense of alleged horizontal conspiracy claims arising out of resolution of patent infringement litigations.
    • In re Processed Eggs Antitrust Litigation (E.D. Pa.). Served as trial counsel for a defendant national egg producer in a six-week federal antitrust jury trial in which plaintiffs alleged a supply reduction and price fixing conspiracy. Secured complete defense verdict.
    • In re Urethanes Antitrust Litigation (D.N.J.). Represented an international chemical manufacturer in a four-week antitrust trial on price fixing claims brought by opt-out plaintiffs. The case settled favorably prior to verdict.
    • In re Southeast Milk Antitrust Litigation (E.D. Tenn.). Represented a national milk processor trial counsel against claims of price-fixing by a large supermarket chain and a convenience store owner, resulting in a favorable settlement.
    • IMN v. Fresenius (S.D. Ind.). Represented a leading dialysis services provider against claims of monopolization, attempted monopolization, and various state law contract and tort claims based on allegedly exclusionary conduct in the dialysis market. Secured dismissal of all antitrust claims.
    • Genus Life Sciences v. Lannett (N.D. Cal.). Represented a national pharmaceutical company in defense of antitrust and false advertising claims based on its product marketing. Secured dismissal with prejudice of all antitrust claims.
    • Highmark Inc. v. U.S. Health Group (E.D. Pa.). Represented a health insurance company as plaintiff in civil RICO, fraud, and civil conspiracy litigation. Reached favorable settlement.
    • In 2023 Law360 recognized Ms. Chapman as a “Rising Star – Competition/Antitrust.”
    • In 2022, Philadelphia Business Journal named Ms. Chapman among the “2022 Best of the Bar.”
    • In 2023, Ms. Chapman was once again listed in The Legal 500 U.S. guide where it was noted she “is well-versed in all stages of litigation particularly in the life sciences, specialty chemicals and tech fields.”
    • In 2022, Ms. Chapman was once again recognized in Who’s Who Legal as a “Future Leader – Competition.”
    • In 2021, Best Lawyers recognized Ms. Chapman as being among the “Ones To Watch” for Antitrust Law in Pennsylvania. This recognition is given to attorneys who are early on in their careers for outstanding professional excellence based off of peer review.
    • In 2019, The Legal Intelligencer named Ms. Chapman among Pennsylvania’s “Lawyers on the Fast Track” in its 2019 Professional Excellence Awards.
    • In 2018, Global Competition Review named Ms. Chapman among the “Litigators of the Week” for achieving a decisive victory for family-owned Pennsylvania egg producer R.W. Sauder, Inc. in a US$1 billion antitrust class action jury trial in Philadelphia Federal Court.
    • Cartel Regulation 2022, U.S. Chapter - (December 16, 2021)
    • Cartel Regulation 2020, U.S. Chapter - (February 14, 2020)
    • The US District Court for the Eastern District of Pennsylvania Finds That a Company was not Part of a Conspiracy to Manipulate the Supply of Eggs and Raise Prices - (September 01, 2018)
    • Young Lawyer Representative, ABA Section of Antitrust Law’s Advertising Disputes and Litigation Committee (2018-2019)
    • Member, Board of Directors, Pennsylvania Court Appointed Special Advocates (2018-2021)
    • Investigative Team Member, Philadelphia Bar Association’s Commission on Judicial Selection (2019-present)
    • United States District Court for the Eastern District of Pennsylvania, Honorable Mary A. McLaughlin